Ads
related to: hodgkin's lymphoma treatment- Long Term Data
Review Long Term Data
Access Information For Physicians.
- Treatment Safety Info
See Treatment Important Safety
Information For Physicians.
- Download Resources
For Healthcare Professionals
About Our Treatment Option.
- Request a Rep Visit
Complete A Form To Schedule A Visit
With A Sales Representative Today.
- Long Term Data
Search results
BioInvent to Host Virtual KOL Event to Highlight Recently Presented Efficacy Data from BioInvent's...
Digital Journal· 17 hours agoLUND, SWEDEN / ACCESSWIRE / May 30, 2024 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy,
Cold agglutinin disease: Causes, symptoms, and treatments
Medical News Today· 1 day agoCold agglutinin disease is a condition that causes low red blood cell (RBC) counts. Cold agglutinin...
Small Business - The Roanoke-Chowan News-Herald | The Roanoke-Chowan News-Herald
Roanoke-Chowan News-Herald· 19 hours agoPhase 3 CARES-310 study found combination of camrelizumab and rivoceranib continued to show sustained long-term survival compared with sorafenib as a first-line treatment ...
Small Business - The Roanoke-Chowan News-Herald | The Roanoke-Chowan News-Herald
Roanoke-Chowan News-Herald· 7 days ago- Beneficial clinical responses observed with EO2463 monotherapy already at 6 weeks and complete response rate of 78% in patients treated with EO2463 upon addition of lenalidomide ± rituximab - EO2463 rapidly expands memory CD8+ T cells specific
A prom night prescription for teenage patients at Children’s National Hospital
Washington Post· 7 days agoDespite being nicknamed for the Disney character “Belle,” recent high school grad Isabelle Ornquist...
Earnings call: Cellectis reports an additional investment of $140 million from AstraZeneca By...
Investing.com· 11 hours agoIn their first quarter 2024 earnings call, Cellectis, a biopharmaceutical company, presented a...
Anti-Cancer Drug Pembrolizumab: Frequently Used Alone Or With Other Treatments
Forbes· 4 days agoPembrolizumab, sold as Keytruda by Merck & Co., was one of the first inhibitors to hit the market. A...
Cell therapy reckoning: Pivot to autoimmune leaves unmet need in oncology
FierceBiotech· 17 hours agoThis story is part 2 in a four-part series about cell therapy created by the Fierce Biotech team....
The Health Scare That Pushed Jonathan Yeo to Paint, and Why King Charles Had Him Seeing Red
The Wall Street Journal· 3 days agoThe royal portraitist wasn’t sure he’d end up a painter, but a cancer diagnosis changed everything....
Cellectis Reports Financial Results for First Quarter 2024
Morningstar· 2 days ago• Cellectis announced completion of the additional equity investment of $140M by AstraZeneca • Cash position of $143 million as of March 31, 20241; cash runway projection into 20262 • Conference call and webcast scheduled for tomorrow, May 29, 2024